Trials / Unknown
UnknownNCT04653649
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
Immunotherapy With Autologous CAR30 T Cells for Patients With Classic Hodgkin Lymphoma and Non-Hodgkin T-cell Lymphoma With CD30 Expression.
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
HSP-CAR30 is a cell suspension of genetically modified T-cells to express a second generation (4-1BBz) chimeric antigen receptor (CAR) directed against CD30. This is a phase I/IIa, interventional, single arm, open label, treatment study to evaluate the safety, tolerability and efficacy of HSP-CAR30 in patients with relapsed/refractory Hodgkin lymphoma and relapsed/refractory T-cell lymphoma expressing CD30.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HSP-CAR30 | Anti-CD30 CAR T-cells |
Timeline
- Start date
- 2020-09-29
- Primary completion
- 2023-12-30
- Completion
- 2023-12-30
- First posted
- 2020-12-04
- Last updated
- 2020-12-04
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT04653649. Inclusion in this directory is not an endorsement.